Anti-TSH receptor antibodies as predictors of the severity and outcome of endocrine ophthalmopathy in the patients presenting with Graves' disease

Sviridenko N.Iu.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossii

Likhvantseva V.G.

Tsentral'naia klinicheskaia bol'nitsa RAN, Moskva

Belovalova I.M.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossii

Sheremeta M.S.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossii

Tabeeva K.I.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossii

Anti-TSH receptor antibodies as predictors of the severity and outcome of endocrine ophthalmopathy in the patients presenting with Graves' disease

Authors:

Sviridenko N.Iu., Likhvantseva V.G., Belovalova I.M., Sheremeta M.S., Tabeeva K.I.

More about the authors

Journal: Problems of Endocrinology. 2011;57(2): 23‑26

Downloaded: 117

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Sviridenko NIu, Likhvantseva VG, Belovalova IM, Sheremeta MS, Tabeeva KI. Anti-TSH receptor antibodies as predictors of the severity and outcome of endocrine ophthalmopathy in the patients presenting with Graves' disease. Problems of Endocrinology. 2011;57(2):23‑26. (In Russ.)

Close metadata

Recommended articles:

Glucocorticoid-resistant forms of endocrine ophthalmopathy. Russian Annals of Ophthalmology. 2024;(6):125-130

A total of 139 patients (278 eyes) presenting with Graves' disease (GD) and endocrine ophthalmopathy (EOP) were examined. The age of 35 men and 104 women ranged from 17 to 71 years. All of them were tested for the functional activity of the thyroid gland and underwent standard ophthalmologic examination; anti-TSH receptor antibodies were measured. Both the activity and severity of EOP were verified as recommended by the European Group on Graves' Orbitopathy (EUGOGO) It was shown that the frequency of detection of anti-TSH receptor antibodies and their titers in patients with GD and EOP depended on the activity of the intraorbital process and the severity of EOP manifestations. The functional state of the thyroid gland also influenced the level of anti-TSH receptor antibodies level during the active phase unlike that in the inactive phase. The in-depth analysis of the relationship between the level of anti-TSH receptor antibodies and clinical characteristics of either EOP (activity, severity, manifestation of selected clinical symptoms) or GD (thyrotoxicosis, euthyroidism, hypothyroidism) demonstrated the possibility to use these characteristics as the factors predicting the severity and outcome of EOP. Also, they may be helpful for the choice of a therapeutic strategy for the treatment of such patients.

Keywords:

endocrine ophthalmopathy

Graves' disease

anti-TSH receptor antibodies

Authors:

Sviridenko N.Iu.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossii

Likhvantseva V.G.

Tsentral'naia klinicheskaia bol'nitsa RAN, Moskva

Belovalova I.M.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossii

Sheremeta M.S.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossii

Tabeeva K.I.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossii

List of references:

Wiersinga W.M., Kahaly G.J. (eds.) Graves' Orbitopathy: A Multidisciplinary Approach. Basel Karger 2007;41-55.
Drexhage H.A. Are there more than antibodies to the thyroid-stimulating hormone receptor that meet the eye in Graves' disease? Endocrinology 2006;147:1:9-12.
Bartalena L., Wiersinga W.M., Pinchera A. Graves' ophthalmopathy: state of the art and perspectives. J Endocrinol Invest 2004;27:3:295-301.
Agretti P., De Marco G., De Servi M. et al. Evidence for protein and mRNA TSHr expression in fibroblasts from patients with thyroid-associated ophthalmopathy (TAO) after adipocytic differentiation. Eur J Endocrinol 2005;152:5:777–784.
Wakelkamp I.M., Bakker O., Baldeschi L. et al. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clin Endocrinol 2003;58:3:280-287.
Bahn R.S., Gorman C.A. Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol Metab Clin North Am 1987;16:2:391-407.
Mourits M.P., Prummel M.F., Wiersinga W.M., Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1997;47:1:9-14.
Werner S.C. Modification of the classification of the eye changes of Graves' disease. Am J Ophthalmol 1977;83:5:725-727.
Bartalena L., Baldeschi L., Dickinson A. et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008;158:3:273-285.
Eckstein A.K., Plicht M., Lax H. et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006;91:9:3464-3470.

Close metadata